Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal CancerReport as inadecuate


Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer


Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer - Download this document for free, or read online. Document in PDF available to download.

1

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan

2

Cancer Center, Kumamoto University Hospital, Kumamoto 860-8556, Japan





*

Author to whom correspondence should be addressed.



Academic Editor: Peter J. K. Kuppen

Abstract Outcomes for metastatic colorectal cancer mCRC patients have been improved by treatment with anti-epidermal growth factor receptor anti-EGFR antibodies, particularly when combined with predictive biomarkers to select patients lacking RAS mutations. New technologies such as liquid biopsy and next-generation sequencing have revealed that potential mechanisms of resistance to anti-EGFR therapies act through acquired mutations of KRAS and the EGFR ectodomain. Mutations in cross-talking molecular effectors that participate in downstream EGFR signaling are also negative predictors for anti-EGFR therapy. In the current review, we describe recent advances in anti-EGFR therapy and discuss new treatment strategies to target downstream RAS-MAPK signaling in mCRC. View Full-Text

Keywords: metastatic colorectal cancer; epidermal growth-factor receptor signaling EGFR; chemotherapy; secondary resistance metastatic colorectal cancer; epidermal growth-factor receptor signaling EGFR; chemotherapy; secondary resistance





Author: Yuji Miyamoto 1, Koichi Suyama 2 and Hideo Baba 1,*

Source: http://mdpi.com/



DOWNLOAD PDF




Related documents